Abstract:
In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Abstract:
Methods for introducing a linear nucleic acid molecule of interest into a cell comprising a cell wall include use of nanoparticles coated with polyethylene glycol. In some embodiments, the cell comprising a cell wall is a plant cell. Methods include genetically or otherwise modifying plants and for treating or preventing disease in plant cells comprising a cell wall. Transgenic plants include a nucleic acid molecule of interest produced by regeneration of whole plants from plant cells transformed with linear nucleic acid molecules.
Abstract:
Provided are methods for introducing a molecule of interest into a plant cell having a cell wall by using a QD-peptide conjugate having a quantum dot (QD) with one or more cell penetrating peptides (CPPs). Methods are provided for genetically or otherwise modifying plants and for treating or preventing disease in plant cells comprising a cell wall.
Abstract:
The invention features compounds of the general formula: B-L-M where B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an imaging moiety; and L is a linker coupling B to M. The invention also features methods of use of the compounds in, for example, treating conditions such as viral infections and pain, as well as in labeling nerve cells.
Abstract:
A vehicle wiper assembly includes a wiper blade configured to wipe a surface, an armature, and an actuator. The armature has a first end spaced from a second end, and is coupled with the wiper blade at the first end, and coupled to a pivot mechanism at the second end. The pivot mechanism is configured to allow the wiper blade to articulate about the second end in a direction substantially away from the surface and between a wiping position and a parked position. The actuator is provided in mechanical communication with the armature and is configured to receive an electrical actuation signal to transition the wiper blade between a wiping position and the parked position, where the wiper blade is in contact with the surface while in the wiping position, and is separated from the surface while in the parked position.
Abstract:
A compound for delivering a non-cytotoxic therapeutic moiety into nerve cells, the compound having the general formula: B-L-TM where: B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and L is a linker coupling B to TM.
Abstract:
The subject invention provides, for example, a novel approach to specifically induce intranasal and/or oral mucosal as well as humoral antibody response by administrating a mucosal delivery pentabody complex (MDPC). The MDPC is a complex formed by mixing a target antigen and a mucosal delivery pentabody (MDP) that has a strong affinity to the target antigen. The MDP is a fusion protein of a single domain antibody (sdAb; which binds to the target antigen specifically) to a pentamerization domain (which can include the B-subunit of an AB5 toxin family, including the B subunit of cholera toxin (CT) or heat-labile toxin (LT)). The pentamerization domain can self-assemble into a pentamer, through which a pentameric single domain antibody, or a pentabody, is formed.
Abstract:
A method of introducing a molecule of interest into a plant cell having a cell wall includes interacting a gamma-zein peptide with a molecule of interest to form a gamma-zein linked structure. The gamma-zein linked structure is then placed in contact with the plant cell having a cell wall, and allowing uptake of the gamma-zein linked structure into the plant cell. Alternatively, a gene of interest can be expressed in a plant cell having an intact cell wall by interacting a gamma-zein peptide with the gene of interest to form a gamma-zein linked gene structure, allowing uptake of the gamma-zein linked gene structure into the plant cell, and expressing the gene of interest in the plant cell and its progeny.
Abstract:
This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic Clostridium perfringens (Cp) α-toxin protein (Mcpa). Utility of this vaccine was demonstrated by reduction of lesion severity in NE challenge trails, for example. Also disclosed herein are novel approaches for producing this vaccine in significant quantities. One exemplified approach involves producing NE vaccine (mutated alpha toxin) in bacterial expression systems, preferably utilizing the Pseudomonas fluorescens system, for commercial use in controlling NE in the poultry industry. The subject vaccines can be administered preferably to chickens in several different ways. A novel, Type VI alpha toxin from chicken isolates of Cp is also disclosed.
Abstract:
The invention features compounds of the general formula: B-L-M where B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an imaging moiety; and L is a linker coupling B to M. The invention also features methods of use of the compounds in, for example, treating conditions such as viral infections and pain, as well as in labeling nerve cells.